Determination of 5-azacitidine in human plasma by LC–MS/MS: application to pharmacokinetics pilot study in MDS/AML patients

50–794_Vidaza_Pharmr_P1.pdf, (n.d.). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/50-794_Vidaza_Pharmr_P1.pdf (accessed August 27, 2021).

Tobiasson M, Abdulkadir H, Lennartsson A, Katayama S, Marabita F, Paepe AD, Karimi M, Krjutskov K, Einarsdottir E, Grövdal M, Jansson M, Azenkoud AB, Corddedu L, Lehmann S, Ekwall K, Kere J, Hellström-Lindberg E, Ungerstedt J (2017) Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease. Oncotarget 8:28812–28825. https://doi.org/10.18632/oncotarget.15807

Article  PubMed  PubMed Central  Google Scholar 

Stresemann C, Lyko F (2008) Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 123:8–13. https://doi.org/10.1002/ijc.23607

Article  CAS  PubMed  Google Scholar 

Adès L, Itzykson R, Fenaux P (2014) Myelodysplastic syndromes. Lancet Lond Engl 383:2239–2252. https://doi.org/10.1016/S0140-6736(13)61901-7

Article  Google Scholar 

Min C, Moore N, Shearstone JR, Quayle SN, Huang P, van Duzer JH, Jarpe MB, Jones SS, Yang M (2017) Selective inhibitors of histone deacetylases 1 and 2 synergize with azacitidine in acute myeloid leukemia. PLoS ONE 12:e0169128. https://doi.org/10.1371/journal.pone.0169128

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042–2054. https://doi.org/10.1056/NEJMra023075

Article  CAS  PubMed  Google Scholar 

vidaza-epar-product-information_fr.pdf, (n.d.). https://www.ema.europa.eu/en/documents/product-information/vidaza-epar-product-information_fr.pdf (accessed September 6, 2021).

Santini V (2019) How I treat MDS after hypomethylating agent failure. Blood 133:521–529. https://doi.org/10.1182/blood-2018-03-785915

Article  CAS  PubMed  Google Scholar 

Font P (2011) Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia. Adv Ther 28(Suppl 3):1–9. https://doi.org/10.1007/s12325-011-0002-8

Article  CAS  PubMed  Google Scholar 

Clavio M, Crisà E, Miglino M, Guolo F, Ceccarelli M, Salvi F, Allione B, Ferrero D, Balleari E, Finelli C, Poloni A, Selleri C, Danise P, Cilloni D, Di Tucci AA, Cametti G, Freilone R, Fanin R, Bigazzi C, Zambello R, Crugnola M, Oliva EN, Centurioni R, Alesiani F, Catarini M, Castelli A, Abbadessa A, Capalbo SF, Musto P, Angelucci E, Santini V (2021) Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. Cancer 127:2015–2024. https://doi.org/10.1002/cncr.33472

Article  CAS  PubMed  Google Scholar 

onureg-epar-public-assessment-report_en.pdf, (n.d.). https://www.ema.europa.eu/en/documents/assessment-report/onureg-epar-public-assessment-report_en.pdf (accessed May 3, 2022).

Fanciullino R, Mercier C, Serdjebi C, Berda Y, Fina F, Ouafik L, Lacarelle B, Ciccolini J, Costello R (2015) Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome, Pharmacogenet. Genomics 25:317–321. https://doi.org/10.1097/FPC.0000000000000139

Article  CAS  Google Scholar 

Fanciullino R, Mercier C, Serdjebi C, Venton G, Colle J, Fina F, Ouafik L, Lacarelle B, Ciccolini J, Costello R (2015) Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale. Pharmacogenomics 16:1907–1912. https://doi.org/10.2217/pgs.15.135

Article  CAS  PubMed  Google Scholar 

Fiche info - VIDAZA 25 mg/ml poudre pour suspension injectable - Base de données publique des médicaments, (n.d.). https://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=61118337 (accessed September 13, 2021).

Vigneron J, Astier A, Trittler R, Hecq JD, Daouphars M, Larsson I, Pourroy B, Pinguet F (2013) SFPO and ESOP recommendations for the practical stability of anticancer drugs: an update. Ann Pharm Fr 71:376–389. https://doi.org/10.1016/j.pharma.2013.06.002

Article  CAS  PubMed  Google Scholar 

Li D, Zhang T, Kou L, Zhang Y, Sun J, He Z (2013) Development of a supercritical fluid chromatography-tandem mass spectrometry method for the determination of azacitidine in rat plasma and its application to a bioavailability study. Mol Basel Switz 19:342–351. https://doi.org/10.3390/molecules19010342

Article  CAS  Google Scholar 

Zhao M, Rudek MA, He P, Hartke C, Gore S, Carducci MA, Baker SD (2004) Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 813:81–88. https://doi.org/10.1016/j.jchromb.2004.09.012

Article  CAS  PubMed  Google Scholar 

Anders NM, Wanjiku TM, He P, Azad NS, Rudek MA (2016) A robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of 5-azacytidine. Biomed Chromatogr 30:494–496

Article  CAS  PubMed  Google Scholar 

guideline-bioanalytical-method-validation_en.pdf, (n.d.). https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf (accessed June 13, 2022).

C. for D.E. and Research, Bioanalytical Method Validation Guidance for Industry, US Food Drug Adm. (2020). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry (accessed September 14, 2021).

Ciccolini J, Dahan L, André N, Evrard A, Duluc M, Blesius A, Yang C, Giacometti S, Brunet C, Raynal C, Ortiz A, Frances N, Iliadis A, Duffaud F, Seitz J-F, Mercier C (2010) Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol Off J Am Soc Clin Oncol 28:160–165. https://doi.org/10.1200/JCO.2009.24.4491

Article  CAS  Google Scholar 

Fanciullino R, Farnault L, Donnette M, Imbs D-C, Roche C, Venton G, Berda-Haddad Y, Ivanov V, Ciccolini J, Ouafik L, Lacarelle B, Costello R (2018) CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine. Blood Adv 2:462–469. https://doi.org/10.1182/bloodadvances.2017014126

Article  CAS  PubMed  PubMed Central  Google Scholar 

Donnette M, Ciccolini J, Pissier C, Costello R, Duffaud F, Salas S, Farnault L, Tichadou A, Arcani R, Jarrot PA, Ouafik LH, Venton G, Fanciullino R (2021) High incidence of CDA deficiency in patients with hematological malignancies: perspectives and therapeutic implications. Ann Oncol Off J Eur Soc Med Oncol 32:684–686. https://doi.org/10.1016/j.annonc.2021.01.072

Article  CAS  Google Scholar 

Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A, Terse P, Covey J, Chan K, Ling Y, Engelke KJ, Sekeres MA, Tiu R, Maciejewski J, Radivoyevitch T, Saunthararajah Y (2013) Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy, Clin Cancer Res Off J Am Assoc. Cancer Res 19:938–948. https://doi.org/10.1158/1078-0432.CCR-12-1722

Article  CAS  Google Scholar 

留言 (0)

沒有登入
gif